Pay in 4 interest-free payments of $5.27 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Implication of intestinal microbiota in the etiopathogenesis of fibromyalgia: a systematic review
The dispersion between Novo and Lilly again goes to show the incredible power of competition to dictate stock outcomes: despite Novos excellent financial performance since 2023 (31% growth in 2023, 25% growth in 2024, 48% EBIT margins), the stock has declined because of competition: investors think Eli Lilly is the emerging winner within GLP-1s, given the stronger weight loss profile of tirzepatide (Mounjaro/Zepbound) versus semaglutide (Ozempic/Wegovy), and Lillys more attractive weight loss pipeline assets
Ne le rate pas
They can help: Improve lipid disorders and fatty liver disease Lower blood pressure Reduce the risk of kidney and heart disease Delay the progression of a diabetes complication called diabetes-related nephropathy Most of these drugs are given through injections, but there is one that comes in pill form
Please also recommend this newsletter to friends and colleagues - its free
US$ 23.80
US$ 27.74
US$ 27.59
US$ 28.96
US$ 29.89
US$ 22.59
